Download PDF
Exp Clin Endocrinol Diabetes 1983; 81(2): 222-227
DOI: 10.1055/s-0029-1210229
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Receptor Binding of STS 5573)

G. Kaupmann1 , J. Schlegel1 , B. Eychenne2 , K. Schubert1
  • 1Academy of Sciences of the GDR, Research Centre of Molecular Biology and Medicine, Central Institute of Microbiology and Experimental Therapy (Director: Prof. Dr. U. Taubeneck), Jena/GDR
  • 2Inserm U 33 Lab Hormones (Head: Prof. Dr. E. E. Baulieu), Bicêtre/France
3) Supported in part by the WHO Special Programme of Research in Human Reproduction, Project 78100.
Further Information

Publication History

1982

Publication Date:
17 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Binding of the new progestagen STS 557 (17α-cyanomethyl-17β-hydroxy-estra-4,9-dien-3-one) to progesterone receptors was investigated by competition experiments using cytosol preparations from chick oviduct, rat uterus, rabbit uterus and human endometrium. A high competitive potency of STS 557 was found in the mammalian systems used. The binding affinity was about 20% that of progesterone. Binding to cytosol receptors of the chick oviduct was two orders lower.

Five derivatives of STS 557 were compared with respect to progesterone receptor binding by using rabbit uterus cytosol. The hydrogenated 3-oxo compounds exhibited receptor affinities similar to the parent compound as far as the planarity of the steroid ring system was sustained. 5β-H compounds were nearly inactive. Additionally, binding to the androgen receptor of rat prostate cytosol was measured. STS 557 and its planar derivatives were found to be effective competitors for 5α-dihydrotestosterone (DHT) exhibiting binding affinities about one fifth that of DHT. The findings are discussed with respect to the chemical structures and the in vivo effects of STS 557.

      >